Both MMB and pacritinib are potent inhibitors of ACVR1, effectively reducing hepcidin expression via the BMP6/ACVR1/SMAD pathway and restoring the balance of iron in the body, thereby aiding in the production of red blood cells although the benefits of pacritinib versus anemia are not yet well defined (32). The gene discussed is BMP6; the disease is anemia (phenotype).